Upadhayay, ShubhamArthur, RichmondSoni, DivyaYadav, PoonamNavik, UmaShankerSingh, RandhirGurjeet Singh, ThakurKumar, Puneet2024-01-212024-08-142024-01-212024-08-142022-10-291567576910.1016/j.intimp.2022.109382http://10.2.3.109/handle/32116/4343Monkeypox is a zoonotic illness caused by the monkeypox virus (MPXV) that has a similar etiology to smallpox. The first case of monkeypox was reported in Western and Central Africa in 1971, and in 2003, there was an outbreak of monkeypox viruses outside Africa. According to the World Health Organization (WHO) and Center for Disease Control and Prevention (CDC), monkeypox is transmitted through direct contact with infected animals or persons exposed to infectious sores, scabs, or body fluids. Also, intimate contact between people during sex, kissing, cuddling, or touching parts of the body can result in the spreading of this disease. The use of the smallpox vaccine against monkeypox has several challenges and hence anti-virals such as cidofovir, brincidofovir, and tecovirimat have been used for the symptomatic relief of patients and reversing the lesion formation on the skin. Despite the recent outbreak of monkeypox most especially in hitherto non-endemic countries, there is still a lack of definitive treatment for monkeypox. In the present review, emphasis was focused on etiopathology, transmission, currently available therapeutic agents, and future targets that could be explored to halt the progression of monkeypox. From our review we can postulate that owing to the lack of a definitive cure to this reemerging disorder, there is a need for general awareness about the transmission as well as to develop appropriate diagnostic procedures, immunizations, and antiviral medication. � 2022 Elsevier B.V.en-USEtiopathologyInfectionMonkeypoxPreventionTherapeutic targetsVaccinesReviewhttps://linkinghub.elsevier.com/retrieve/pii/S1567576922008669